Sari

Thank you for your replies! It seems that we are quite conservative in our ways. We strive to always deliver RhD compatible PLTs to all patients and currently administer RhIG to all D neg recipients of RhD pos PLTs. This has however led to occasional PLT shortages which is the reason we're re-evaluating our policy. We also have a policy of not collecting apheresis platelets from Kell pos donors, but this is under active re-evaluation also. One further question - if you have seen anti-D develop due to incompatible PLT transfusion, why do you choose to not administer RhIG to all RhD neg patients receiving RhD pos PLTs? Is it a financial issue, or have you seen adverse effects from RhIG in these patients?

Hi everyone, At our blood bank we're reviewing our policy concerning RhD incompatible platelet tranfusion. I'd like to hear about what sort of policies you guys have at your blood bank/hospital. - Do you administer RhD pos platelets to RhD neg patients? In what situations (always, only when there is a shortage of RhD neg platelets)? To which patient groups do you not recommend RhD incompatible platelets (women < 50 yrs, patients who receive frequent platelet transfusions)? - Do you have a different policy for apheresis and whole blood derived platelets? - Do you administer prophylactic Rh immunoglobulin to these patients (everyone, or selected patient groups)? And now for something completely different... - Do you have a policy concerning Kell positive donors and plateletpheresis? Do you defer these donors, or do you have a policy of not actively recruiting these donors for plateletpheresis? Cheers, Sari